Nov 18, 2020
Dr. Richard Furie discuss his recent involvement with the Phase
3 BLISS-LN clinical trial that is setting the stage for the first
ever FDA approved drug for lupus nephritis.
Dr. Furie is a professor at the Feinstein Institutes for medical research, Northwell Health’s science arm of the health system.
Regarded as one the senior rheumatologists in the New York metropolitan area, he has been on the Boards of Directors of the local chapters of the Arthritis Foundation and the Lupus Alliance of America and has been a member of the Medical-Scientific Advisory Council of the Lupus Foundation of America as well as its Lupus News editorial board. He also is on the Medical and Scientific Advisory Board of the SLE Foundation as well as the Alliance for Lupus Research Scientific Advisory Board.